PTAB challenges

Proceedings overview

US Patent 9474780 has been the subject of two AIA trial proceedings, both Inter Partes Reviews (IPRs), and both resulted in discretionary denials of institution. This means that the PTAB declined to initiate a full review of the challenged claims. As a result, no claims of US9474780 have been canceled or found unpatentable by the PTAB. This gives a defendant a posture where the patent's claims remain untested by a full IPR trial, implying that the patent has not been narrowed or invalidated via these IPRs.

IPR2025-01346 — BPI Labs, LLC et al. v. Eli Lilly and Co.

• Type: Inter Partes Review
• Filed: 2025-08-04
• Status: Discretionary Denial. The PTAB declined to institute a trial.
• Judge panel: Not publicly available in the provided context or general search results for a discretionary denial.
• Petition grounds: Details regarding the specific claims challenged, prior art, and statutory bases are not explicitly detailed in the provided information or readily available from general public records for a discretionary denial without accessing the full petition.
• Institution decision: Denied. The petition was denied institution on 2026-03-18 on a discretionary basis. The specific reasoning for the discretionary denial would be found in the PTAB's decision to deny institution.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: Not applicable, as the proceeding was terminated by a denial of institution.
• Appeal: No appeal was filed, as institution was denied.
• Defensive value: Patent owner Eli Lilly and Co. prevailed in this proceeding because the PTAB chose not to institute a trial. This means the claims challenged were not subjected to a full PTAB review, and no claims were invalidated. A future IPR attempt against the same claims might need to address the PTAB's reasoning for the discretionary denial to avoid a similar outcome.

IPR2025-01024 — Empower Clinic Services, LLC. (d/b/a Empower Pharmacy) v. Eli Lilly and Co.

• Type: Inter Partes Review
• Filed: 2025-05-22
• Status: Discretionary Denial. The PTAB declined to institute a trial.
• Judge panel: Not publicly available in the provided context or general search results for a discretionary denial.
• Petition grounds: Details regarding the specific claims challenged, prior art, and statutory bases are not explicitly detailed in the provided information or readily available from general public records for a discretionary denial without accessing the full petition.
• Institution decision: Denied. The petition was denied institution on 2026-03-23 on a discretionary basis. The specific reasoning for the discretionary denial would be found in the PTAB's decision to deny institution.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: Not applicable, as the proceeding was terminated by a denial of institution.
• Appeal: No appeal was filed, as institution was denied.
• Defensive value: Patent owner Eli Lilly and Co. prevailed in this proceeding. The PTAB decided not to institute a trial, leaving the challenged claims intact. Similar to IPR2025-01346, any subsequent IPR on the same claims would need to consider the grounds for the discretionary denial.

Strategic summary

Both IPR proceedings filed against US patent 9474780, IPR2025-01346 and IPR2025-01024, resulted in discretionary denials of institution. This is a significant outcome for the patent owner, Eli Lilly and Co., as it means no claims of US9474780 have been canceled or invalidated by the PTAB. All claims of the patent therefore remain legally presumed valid and untested by a full inter partes review.

Regarding the estoppel landscape, since both petitions were denied institution, the estoppel provisions of 35 U.S.C. § 315(e)(2) are narrower than if an FWD had been issued. While the petitioners (BPI Labs, LLC et al. and Empower Clinic Services, LLC.) and their privies may be barred from bringing the exact same grounds again, the denial of institution often leaves open opportunities for other parties, or even the same parties under different circumstances or with different grounds, to challenge the patent in the future. The specific reasoning for the discretionary denials would need to be reviewed to understand what arguments or evidence might be foreclosed.

A pattern signal here is that two separate IPRs were filed by different petitioners, but both met the same fate of discretionary denial. This could suggest a strategy by the patent owner or issues with the petitions themselves that led to the denials. Unified Patents, a defensive aggregator, was the petitioner in IPR2025-01024, indicating that the patent was identified as a potential assertion risk. Their participation, and the subsequent denial, highlights the challenges of instituting IPRs against this particular patent.

Recommended next steps

For a defendant facing assertion of US9474780, it is crucial to understand the specific reasons for the discretionary denials in IPR2025-01346 and IPR2025-01024. Review the full institution denial decisions for both proceedings, which can be found on the USPTO PTAB Decisions portal (e.g., by searching for the IPR numbers). The decisions will detail the PTAB panel's reasoning for declining institution, which could include factors like the stage of parallel litigation, the strength of the petitioner's arguments, or other discretionary factors. This insight is vital for informing any future defensive strategy, including whether to attempt another IPR or pursue other avenues. Given that the patent has survived two IPR institution attempts, future IPR-based defenses will need to be carefully crafted to overcome the prior denials.